Episode 205: Dr Meriem Sefta and Amanda Coble – Unlocking Diagnostic Innovation: Inside Owkin’s Partnership With Proscia
Today my guests are Dr Meriem Sefta, Chief Diagnostics Officer at Owkin, and Amanda Coble, Senior Director of Product at Proscia.
What we discuss with Amanda and Dr Sefta:
- The history of Owkin
- Founding vision and early challenges
- Deep learning in pathology
- Mission and Precision Oncology
- Digital pathology and AI integration
- Biomarker screening products like MSIntuit CRC
- Outcome prediction solutions like RLapseRisk BC
- Partnership with Proscia
- The future of pathology with AI
- Interoperability and collaboration
Disclaimer:
MSIntuit CRC, BRCAura BC, and RlapsRisk BC are under development and not for clinical use. They are not FDA cleared or approved in the USA. BRCAura BC and RlapsRisk BC are developed within the PortrAIt consortium, a french consortium financed by the government within the framework of France 2030 and by the European Union – Next Generation EU within the framework of the France Relance Plan.
Owkin interoperability with Proscia’s software is for Research Use Only. Not for use in diagnostic procedures.
Links for this episode:
Pathologists’ Assistant Shadowing Network
Owkin And Proscia Expand Access To AI Pre-Screening For Colorectal Cancer Patients
People of Pathology Podcast:
Responses